Health ProductsDear Healthcare Professional Letter

Archived – Important Safety Information on Euro-K and Riva-K Sustained Release Potassium Supplements

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Euro-K and Riva-K Sustained Release Potassium Supplements

September 1, 2004

Dear Pharmacist,

Health Canada is advising consumers about a recall of certain sustained release potassium replacement products distributed in Canada by Euro-Pharm International Canada Inc. and Laboratoire Riva Inc. Recent testing has led to the conclusion that the release of potassium by these products may be unreliable. This recall includes the following products: Euro-K 8 SR, Euro-K 20 SR, Euro-K 600 SR, Riva-K 8 SR, and Riva-K 20 SR. Some of the products released potassium at a rate or quantity less than specified, while others released potassium at a rate that was greater than specified.

All lots of Euro-K and Riva-K are being recalled with the exception of Euro-K lots EKT 404 and EKT 405. These two lots are currently being assessed and the results will be provided to pharmacists via a separate communication.

As a precaution, Health Canada is advising consumers to return these products to their pharmacists for a suitable alternative if necessary.

Those individuals, with heart, liver or kidney conditions, taking any of these potassium supplements on the advice of a physician should consult their physician to assess the adequacy of their potassium replacement.

The following lots release potassium at levels less than specified, Euro-K 8 SR capsules Lot EKE302 Exp 2005 OC; Riva-K 8 SR capsules Lot KERK 804A Exp 2005 MR and Riva-K 8 SR Lots KJRK 805A and KJRK 805B Exp 2005 AL.

Many patients with low potassium are asymptomatic and the condition is usually diagnosed by a blood test. Symptoms can vary greatly between individuals ranging anywhere from fatigue, muscle pain and weakness in mild hypokalemia, to cardiac arrhythmias in the severe end of the spectrum.

Specific potential adverse reactions which could occur with any product which releases potassium at a rate greater than specified are; gastrointestinal adverse events, such as nausea, vomiting, abdominal pain, diarrhea and indigestion. The range of product specification failures make it difficult to accurately predict all of the symptoms which may occur as a result of the use of these products.

To date there have been no adverse reactions reported relating to use of these products in Canada. Specification tests which brought the risks to attention were conducted as part of routine testing operations within Health Canada.

Pharmacists are being requested to assist their customers in obtaining alternate potassium replacement products as continued potassium supplementation may be important to prevent hypokalemia from developing.

Individuals who have received Euro-K 8 or Riva-K 8 SR should be advised to contact their physicians to have their potassium status assessed.

The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of serious and/or unexpected adverse reactions in patients receiving these products should be reported to Health Canada at the following address:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information.

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For further information, please contact the nearest Regional Operational Centre (see list below).

Regional Operational Centres

British Columbia, Alberta, Northwest Territories, Yukon
Operational Manager
3155 Willingdon Green
Burnaby, British Columbia V5G 4P2
Phone (604) 666-3350 or Fax (604) 666-3149

Manitoba, Saskatchewan
Operational Manager
510 Lagimodiere Blvd
Winnipeg, Manitoba R2J 3Y1
Phone (204) 983-5490 or Fax (204) 984-2155

Ontario, Nunavut
Operational Manager
2301 Midland Ave.
Toronto, Ontario M1P 4R7
Phone (416) 973-1600 or Fax (416) 954-4583

Quebec
Operational Manager
1001 Rue St-Laurent Ouest
Longueuil, Quebec J4K 1C7
Phone (450) 646-1353 or Fax (450) 928-4455

Atlantic
Operational Manager
Suite 1625, 16th Floor
1505 Barrington Street
Halifax, Nova Scotia B3J 3Y6
Phone (902) 426-2160 or Fax (902) 426-6676

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime